Bristol-Myers Squibb Profit Margin 2006-2019 | BMY

Current and historical gross margin, operating margin and net profit margin for Bristol-Myers Squibb (BMY) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Bristol-Myers Squibb net profit margin as of June 30, 2019 is 26.14%.
Bristol-Myers Squibb Annual Profit Margins
Bristol-Myers Squibb Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $80.921B $22.561B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $341.878B 14.89
Roche Holding AG (RHHBY) Switzerland $235.862B 0.00
Merck (MRK) United States $210.028B 17.27
Pfizer (PFE) United States $203.709B 12.00
Novartis AG (NVS) Switzerland $197.630B 16.99
Novo Nordisk (NVO) Denmark $117.169B 20.70
AstraZeneca (AZN) United Kingdom $111.536B 21.58
Sanofi (SNY) France $109.180B 13.41
Eli Lilly (LLY) United States $106.323B 19.84
AbbVie (ABBV) United States $104.351B 8.36
GlaxoSmithKline (GSK) United Kingdom $101.265B 12.73
Bayer (BAYRY) Germany $69.755B 10.16
H Lundbeck (HLUYY) Denmark $6.896B 9.95